2021至2022年中国13个地区成人盲与视力损伤的横断面调查
2021至2022年在中国13个省、自治区、直辖市对18岁及以上成人开展以人群为基础的横断面调查,共93 123人完成,应答率76.2%。按较好眼最佳矫正视力统计,盲率0.30%、中重度视力损伤(低视力)率2.44%、轻度视力损伤率5.02%。致盲和低视力前三位眼病为白内障(42.62%)、未矫正的屈光不正(14.52%)和病理性近视眼(3.02%)。
要点
- 2021至2022年中国成人盲率为0.30%(280/93 123),低视力率为2.44%(2 270/93 123)。
- 按较差眼最佳矫正视力统计,致盲和低视力首位眼病为白内障,占42.62%(1 271/2 982)。
- 病理性近视眼占致盲和低视力原因的3.02%(90/2 982),已成为不可逆盲的首要眼病。
核心结论
- 2021至2022年中国成人盲率和低视力率分别为0.30%和2.44%。
- 白内障仍是导致中国成人盲和低视力的首要眼病。
- 病理性近视眼已成为导致中国人群不可逆盲的首要眼病。
研究设计与样本
- 研究为以人群为基础的横断面调查,于2021至2022年在中国13个省、自治区、直辖市开展。
- 调查对象为18岁及以上成人,分为青年(18~39岁)、中年(40~59岁)及老年人群(≥60岁)。
- 调查项目包括视力、非接触眼压计测量眼压、眼前节情况、眼底情况、非散瞳电脑验光屈光状态及基本人口学资料问卷。
- 采用Cochran-Armitage趋势检验进行统计学处理。
主要发现
- 共93 123名成人完成调查,总应答率76.2%(93 123/122 191),平均年龄48.8岁(范围18~101岁)。
- 男性37 725名(40.5%),女性55 398名(59.5%);18~39岁32 357名(34.75%),40~59岁29 127名(31.28%),≥60岁31 639名(33.97%),50岁及以上48 763名(52.36%)。
- 按较好眼最佳矫正视力统计,盲280例(0.30%)、中重度视力损伤(低视力)2 270例(2.44%)、轻度视力损伤4 679例(5.02%)。
- 按较差眼最佳矫正视力统计,在2 982名盲和低视力者中,前三位眼病(不包括眼外伤和不明原因眼底病)为白内障1 271名(42.62%)、未矫正的屈光不正433名(14.52%)、病理性近视眼90名(3.02%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the prevalence of blindness and visual impairment in adults and the related causes in China. Methods: A population-based cross-sectional survey was conducted during 2021 and 2022 among 13 provinces, municipalities, and autonomous regions, including Beijing, Hebei, Jiangsu, Shanghai, Guangdong, Henan, Shanxi, Ningxia Hui Autonomous Region, Chongqing, Yunnan, Sichuan, Heilongjiang, and Liaoning. Respondents were adults aged 18 years and above, and were classified into groups of young adults (18 to 39 years), middle-age adults (40 to 59 years), and the elderly (≥60 years). The examinations included visual acuity measurement, non-contact tonometry, slit-lamp examination, fundus photography, automatic refraction (non-mydriasis), and demographics (questionnaire). The diagnosis and distribution of eye diseases were analyzed. The Cochran-Armitage test was used for statistical processing. Results: A total of 93 123 adults with a mean age of 48.8 years (range, 18 to 101 years) completed the survey, and the response rate was 76.2% (93 123/122 191). There were 37 725 males (40.5%) and 55 398 females (59.5%), while 32 357 (34.75%) were aged 18 to 39, 29 127 (31.28%) were aged 40 to 59, and 31 639 (33.97%) were aged≥60. According to the best-corrected visual acuity (BCVA) in the better eye of 93 123 adults, the blindness, moderate to severe visual impairment (low vision), and mild visual impairment were found in 280, 2 270, and 4 679 patients, respectively. Based on BCVA of the worse eye, the top three causes of blindness and low vision were cataract (1 271/2 982, 42.62%), uncorrected refractive error (433/2 982, 14.52%), and pathological myopia (90/2 982, 3.02%), without considering trauma or other undefined fundus diseases. Conclusions: From 2021 to 2022, the prevalence rates of blindness and low vision in Chinese adults were 0.30% and 2.44%, respectively. Cataract was the primary eye disease leading to blindness and low vision, and pathological myopia became the major cause of irreversible blindness in the population. 目的: 了解我国成人盲和视力损伤情况及其原因。 方法: 横断面研究。于2021至2022年调查我国13个省、自治区、直辖市(北京市、河北省、江苏省、上海市、广东省、河南省、山西省、宁夏回族自治区、重庆市、云南省、四川省、黑龙江省、辽宁省)18岁及以上成人,分为青年(18~39岁)、中年(40~59岁)及老年人群(≥60岁)。调查项目包括视力、眼压(非接触眼压计测量)、眼前节情况、眼底情况、屈光状态(非散瞳电脑验光)以及基本人口学资料等(问卷),进行眼病诊断和分布分析。采用趋势检验进行统计学处理。 结果: 93 123名成人完成调查,总应答率为76.2%(93 123/122 191);平均年龄为48.8岁(范围为18~101岁)。男性37 725名(40.5%),女性55 398名(59.5%)。18~39岁者32 357名(34.75%),40~59岁者29 127名(31.28%),≥60岁者31 639名(33.97%);50岁及以上者48 763名(52.36%)。按视力较好眼的最佳矫正视力统计,成人盲率、中重度视力损伤(低视力)率、轻度视力损伤率分别为0.30%(280/93 123)、2.44%(2 270/93 123)和5.02%(4 679/93 123);按视力较差眼的最佳矫正视力统计,在2 982名盲和低视力者中,致盲和低视力的前3位眼病(不包括眼外伤和不明原因眼底病)分别为白内障(1 271名,占比42.62%)、未矫正的屈光不正(433名,占比14.52%)和病理性近视眼(90名,占比3.02%)。 结论: 2021至2022年我国成人盲率和低视力率分别为0.30%和2.44%。白内障仍是导致我国成人盲和低视力的首要眼病,病理性近视眼已成为导致我国人群不可逆盲的首要眼病。.
引用
- Cao K, Hu AL, Zhou XY, et al. [A cross-sectional survey of blindness and visual impairment among adults in 13 regions of China from 2021 to 2022]. Zhonghua Yan Ke Za Zhi. 2025. PMID: 39939006. doi:10.3760/cma.j.cn112142-20240111-00021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。